• Seer reported the European Patent Office will maintain EP4056263, covering particle-based protein enrichment for proteomics; a written decision is expected in about two months.
• The patent is owned by Brigham and Women’s Hospital, which exclusively licenses it to Seer.
• The U.S. International Trade Commission opened an investigation into Nanomics imports tied to alleged infringement of five Seer U.S. patents.
• Seer is seeking a limited exclusion order targeting Nanomics Proteonano kits and workstations; Brigham and Women’s Hospital joined as co-complainant.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010700PRIMZONEFULLFEED9755430) on July 01, 2026, and is solely responsible for the information contained therein.